These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 479915)

  • 1. Observations on the effect of injection of lymphocytes from multiple sclerosis and Guillain-Barré syndrome in the rabbit eye model.
    Kam-Hansen S; Kristensson K; Link H
    J Neurol Sci; 1979 Jul; 42(2):283-9. PubMed ID: 479915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral nerve P2 basic protein and the Guillain-Barré syndrome. In vitro demonstration of P2-specific antibody-secreting cells.
    Luijten JA; De Jong WA; Demel RA; Heijnen CJ; Ballieux RE
    J Neurol Sci; 1984; 66(2-3):209-16. PubMed ID: 6085109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome.
    Giovannoni G; Hartung HP
    Curr Opin Neurol; 1996 Jun; 9(3):165-77. PubMed ID: 8839607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis.
    Vedeler CA; Matre R; Sadallah S; Schifferli J
    J Neuroimmunol; 1996 Jun; 67(1):17-20. PubMed ID: 8707926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. the role of autoantibody and immune complexes in the pathogenesis of Guillain-Barré syndrome.
    Cook SD; Dowling PC
    Ann Neurol; 1981; 9 Suppl():70-9. PubMed ID: 6452856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors.
    Hartung HP; Hughes RA; Taylor WA; Heininger K; Reiners K; Toyka KV
    Neurology; 1990 Feb; 40(2):215-8. PubMed ID: 2300238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte adherence to myelinated tissue in multiple sclerosis: correlation with disease activity.
    Dore-Duffy P; Donaldson JO; Thompson HG; Leuze M
    Neurology; 1986 Nov; 36(11):1500-3. PubMed ID: 3762966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroimmunological findings in Guillain Barré syndrome, multiple sclerosis, and idiopathic polyneuropathies.
    Dorta-Contreras A; Silva-Somoza R
    Mol Chem Neuropathol; 1996; 28(1-3):279-84. PubMed ID: 8871970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis.
    Sanders ME; Koski CL; Robbins D; Shin ML; Frank MM; Joiner KA
    J Immunol; 1986 Jun; 136(12):4456-9. PubMed ID: 3711661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A study on red blood cell immune function in patients with Guillain-Barré syndrome and multiple sclerosis].
    Qi X; Zhu K; Liu J
    Zhonghua Nei Ke Za Zhi; 1996 Aug; 35(8):517-9. PubMed ID: 9594140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes.
    Sawant-Mane S; Clark MB; Koski CL
    Ann Neurol; 1991 Apr; 29(4):397-404. PubMed ID: 1718212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum antibodies to HTLV-I in human demyelinating disease.
    Epstein L; Blumberg B; Crowley J; Samuel K; Goudsmit J; Cook S; Dowling P
    Acta Neurol Scand; 1987 Apr; 75(4):231-3. PubMed ID: 2884798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte adherence to myelinated tissue in multiple sclerosis.
    Dore-Duffy P; Goertz V; Rothman BL
    J Clin Invest; 1980 Oct; 66(4):843-6. PubMed ID: 6968323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal.
    Chalon MP; Sindic CJ; Laterre EC
    Acta Neurol Scand; 1993 Feb; 87(2):77-82. PubMed ID: 8442399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease.
    Dau PC
    J Neuroimmunol; 1990 Nov; 30(1):15-21. PubMed ID: 2229403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases].
    Shimada K; Koh CS; Yanagisawa N
    Arerugi; 1993 Aug; 42(8):934-40. PubMed ID: 8250733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-mediated Schwann cell cytotoxicity in the Guillain-Barré syndrome.
    Lisak RP; Kuchmy D; Armati-Gulson PJ; Brown MJ; Sumner AJ
    Neurology; 1984 Sep; 34(9):1240-3. PubMed ID: 6540410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells in patients with Guillain-Barré syndrome.
    Yoshii F; Shinohara Y
    J Neurol Sci; 1998 May; 157(2):175-8. PubMed ID: 9619642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barré syndrome: an ultrastructural study of peripheral nerve in 65 patients.
    Brechenmacher C; Vital C; Deminiere C; Laurentjoye L; Castaing Y; Gbikpi-Benissan G; Cardinaud JP; Favarel-Garrigues JP
    Clin Neuropathol; 1987; 6(1):19-24. PubMed ID: 3552352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-mediated demyelination.
    Hartung HP
    Ann Neurol; 1993 Jun; 33(6):563-7. PubMed ID: 8498835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.